Younger patients with high-risk melanoma benefit from adjuvant Sutent

CHICAGO — Sunitinib in the adjuvant setting is associated with greater overall survival in high-risk patients with uveal melanoma, especially younger patients, according to a speaker here.
“We’re starting to figure out metastatic risk for melanoma,” Carol L. Shields, MD, said at Ocular Oncology and Pathology Subspecialty Day preceding the American Academy of Ophthalmology annual meeting. “Gene expression profile neatly separates melanoma into two groups: class 1 with 3% risk for metastatic disease at 4 years and class 2 with an 80% risk.”
Shields said that

Full Story →